{"id":"eribulin-standard-regimen","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Fatigue"},{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Alopecia"},{"rate":"30-50","effect":"Anemia"},{"rate":"5-15","effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eribulin is a non-taxane microtubule inhibitor derived from halichondrin B. It binds to the plus end of microtubules and inhibits their growth and dynamics, causing G2/M phase cell cycle arrest. This mechanism leads to apoptosis in rapidly dividing cancer cells, particularly in breast cancer and other solid tumors.","oneSentence":"Eribulin is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:23.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Liposarcoma"},{"name":"Other solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT07088263","phase":"PHASE3","title":"Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Breast Neoplasms","enrollment":192},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":"Triple Negative Breast Cancer","enrollment":254},{"nctId":"NCT06857305","phase":"PHASE3","title":"Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ma Fei，MD","startDate":"2023-07-13","conditions":"Breast Cancer Metastatic","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eribulin standard regimen","genericName":"Eribulin standard regimen","companyName":"Ma Fei，MD","companyId":"ma-fei-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eribulin is a small molecule used in the treatment of various breast cancer conditions, including metastatic breast cancer, triple negative breast cancer, and HRD-positive/HER2-negative advanced breast cancer. The standard regimen for Eribulin typically involves its administration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}